Effect of 3,4-Dihydroxyacetophenone on Endothelial Dysfunction in Streptozotocin-induced Rats With Type 2 Diabetes

    loading  Checking for direct PDF access through Ovid

Abstract

This study investigated whether 3,4-Dihydroxyacetophenone (DHAP) could improve endothelial function in streptozotocin-induced type 2 diabetic rats. Sprague–Dawley rats were randomly divided into control, diabetic, and diabetic DHAP-treated animals. After treatment with DHAP for 8 weeks, endothelial function was determined by measuring endothelium-dependent vasodilatation (EDV) of the thoracic aorta. Endothelial nitric oxide synthase (eNOS) activity and nitric oxide (NO) production in endothelial cells and nuclear transcription factor kappa B (NF-κB) expression and superoxide anion production in the aorta were determined. DHAP treatment reduced serum levels of triglycerides, cholesterol, malondialdehyde, and tumor necrosis factor α, and enhanced serum adiponectin levels. Endothelium-dependent vasodilatation was significantly attenuated in rats with diabetes and increased significantly after DHAP treatment. NO levels and eNOS activity in endothelial cells were significantly reduced, and NF-κB activation and superoxide production increased in rats with diabetes compared with the control group. DHAP treatment enhanced NO levels and eNOS activity and decreased NF-κB activation and superoxide production. These findings suggest that DHAP could improve endothelial function in streptozotocin-induced type 2 diabetic rats. The mechanism may be related to the enhancement of eNOS activity and NO production by reducing plasma lipid levels, oxidative stress, and inflammatory activity.

Related Topics

    loading  Loading Related Articles